Literature DB >> 2801676

Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus.

S Fiorucci1, L Santucci, F Farroni, M A Pelli, A Morelli.   

Abstract

Pattern of gastric and esophageal acidity were evaluated in 14 patients with endoscopically and histologically proven Barrett's esophagus, in 46 with slight-to-moderate esophagitis, and in 22 healthy subjects. In patients with Barrett's esophagus, LES pressure was considerably lower and percentage exposure to acid was considerably higher than in either patients with esophagitis or controls (p less than 0.001). Percentage of time with esophageal pH below 4 was 33.2% in patients with Barrett's esophagus, 14% in patients with slight-to-moderate esophagitis (p less than 0.001), and 3.4% in controls (p less than 0.001). In patients with Barrett's esophagus, the esophageal exposure to acid was similar in upright and supine positions, and the number of refluxes that lasted longer than 5 min was also greater in these patients than in uncomplicated esophagitis or controls (p less than 0.001). Accordingly, their acid-clearing capacity was markedly reduced (p less than 0.001 vs. control). Omeprazole 20 mg, given once daily, reduced both percentage of time with pH below 4 (p less than 0.001) and the number of episodes longer than 5 min (p less than 0.001), but had no effect on acid clearance. In patients with Barrett's esophagus, omeprazole lowered intragastric acidity by 77.8% (p less than 0.001). Median intragastric pH was 1.9 (1.7-2.1) pretreatment, and 4.5 (4.2-5) during omeprazole (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801676

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

2.  Intragastric acidity and serum gastrin after sufotidine.

Authors:  G S Mela; E Caputo; G Villa; V Savarino; P Zentilin
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 3.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

4.  Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus.

Authors:  M J Collen; D A Johnson
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

5.  The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.

Authors:  Joshua T Watson; Fouad J Moawad; Ganesh R Veerappan; John T Bassett; Corinne L Maydonovitch; John D Horwhat; Roy K H Wong
Journal:  Dig Dis Sci       Date:  2013-07-04       Impact factor: 3.199

6.  24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus.

Authors:  C S Neumann; B T Cooper
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

7.  Esophageal Acid Clearance During Random Swallowing Is Faster in Patients with Barrett's Esophagus Than in Healthy Controls.

Authors:  Christian Lottrup; Anne L Krarup; Hans Gregersen; Per Ejstrud; Asbjørn M Drewes
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.